<div><p>Objectives</p><p>We measured gender differences in “Quality of Care” (QOC) during the first year after initiation of antiretroviral therapy and investigated factors associated with poorer QOC among women.</p><p>Design</p><p>QOC was estimated using the Programmatic Compliance Score (PCS), a validated metric associated with all-cause mortality, among all patients (≥19 years) who initiated ART in British Columbia, Canada (2000–2010).</p><p>Methods</p><p>PCS includes six indicators of non-compliance with treatment initiation guidelines at baseline (not having drug resistance testing before treatment; starting on a non-recommended regimen; starting therapy at CD4<200 cells/mm<sup>3</sup>) and during first-year follow-up (receiving <3 CD4...
Treatment outcomes for antiretroviral therapy (ART) patients may vary by gender, but estimates from ...
Objectives: To determine (1) gender-related differences in antiretroviral therapy (ART) outcomes, an...
Aims: To compare the gender distribution of HIV-infected adults receiving highly active antiretrovir...
We measured gender differences in “Quality of Care” (QOC) during the first year after initiation of ...
OBJECTIVES: We measured gender differences in "Quality of Care" (QOC) during the first year after in...
Objectives: We measured gender differences in ‘‘Quality of Care’ ’ (QOC) during the first year after...
Background Cohort data examining differences by gender in clinical responses to combination antiretr...
Cohort data examining differences by gender in clinical responses to combination antiretroviral ther...
Background: Cohort data examining differences by gender in clinical responses to combination antiret...
Cohort data examining differences by gender in clinical responses to combination antiretroviral ther...
Background: Barriers to HIV treatment among injection drug users (IDU) are a major ...
γ<p>Overall, QOC was better among men, who had a lower mean PCS score of 1.54 (SD = 1.30) compared w...
Background: Antiretroviral therapy (ART) and ambitious treatment strategies such as Treatment as Pre...
OBJECTIVES Gender-specific data on the outcome of combination antiretroviral therapy (cART) are a...
OBJECTIVES: Gender-specific data on the outcome of combination antiretroviral therapy (cART) are a s...
Treatment outcomes for antiretroviral therapy (ART) patients may vary by gender, but estimates from ...
Objectives: To determine (1) gender-related differences in antiretroviral therapy (ART) outcomes, an...
Aims: To compare the gender distribution of HIV-infected adults receiving highly active antiretrovir...
We measured gender differences in “Quality of Care” (QOC) during the first year after initiation of ...
OBJECTIVES: We measured gender differences in "Quality of Care" (QOC) during the first year after in...
Objectives: We measured gender differences in ‘‘Quality of Care’ ’ (QOC) during the first year after...
Background Cohort data examining differences by gender in clinical responses to combination antiretr...
Cohort data examining differences by gender in clinical responses to combination antiretroviral ther...
Background: Cohort data examining differences by gender in clinical responses to combination antiret...
Cohort data examining differences by gender in clinical responses to combination antiretroviral ther...
Background: Barriers to HIV treatment among injection drug users (IDU) are a major ...
γ<p>Overall, QOC was better among men, who had a lower mean PCS score of 1.54 (SD = 1.30) compared w...
Background: Antiretroviral therapy (ART) and ambitious treatment strategies such as Treatment as Pre...
OBJECTIVES Gender-specific data on the outcome of combination antiretroviral therapy (cART) are a...
OBJECTIVES: Gender-specific data on the outcome of combination antiretroviral therapy (cART) are a s...
Treatment outcomes for antiretroviral therapy (ART) patients may vary by gender, but estimates from ...
Objectives: To determine (1) gender-related differences in antiretroviral therapy (ART) outcomes, an...
Aims: To compare the gender distribution of HIV-infected adults receiving highly active antiretrovir...